{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:10:27Z","timestamp":1792069827475,"version":"4.4.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["TRV130"],"award-info":[{"award-number":["TRV130"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.biopsych.2020.02.014","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T18:44:45Z","timestamp":1582569885000},"page":"935-944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["In a Rat Model of Opioid Maintenance, the G Protein\u2013Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain Hypoxia"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5636-4071","authenticated-orcid":false,"given":"Jennifer M.","family":"Bossert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene A.","family":"Kiyatkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Korah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Hoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anum","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Perekopskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruthi","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Fredriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Blough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Stevens","family":"Negus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavin","family":"Shaham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2020.02.014_bib1","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.15585\/mmwr.mm6450a3","article-title":"Increases in drug and opioid overdose deaths\u2014United States, 2000-2014","volume":"64","author":"Rudd","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.biopsych.2020.02.014_bib2","first-page":"1","article-title":"Drug overdose deaths in the United States, 1999-2016","volume":"294","author":"Hedegaard","year":"2017","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.biopsych.2020.02.014_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1146\/annurev-pharmtox-010617-052534","article-title":"The opioid epidemic: Crisis and solutions","volume":"58","author":"Skolnick","year":"2018","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.biopsych.2020.02.014_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.15585\/mmwr.mm6712a1","article-title":"Overdose deaths involving opioids, cocaine, and psychostimulants\u2014United States, 2015-2016","volume":"67","author":"Seth","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.biopsych.2020.02.014_bib5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/jama.1965.03090080008002","article-title":"A\u00a0medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride","volume":"193","author":"Dole","year":"1965","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2020.02.014_bib6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","article-title":"Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction","volume":"35","author":"Jasinski","year":"1978","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2020.02.014_bib7","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A\u00a0comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence","volume":"343","author":"Johnson","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.biopsych.2020.02.014_bib8","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"4","author":"Mattick","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.biopsych.2020.02.014_bib9","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1377\/hlthaff.2012.0846","article-title":"A\u00a0call for evidence-based medical treatment of opioid dependence in the United States and Canada","volume":"32","author":"Nosyk","year":"2013","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.biopsych.2020.02.014_bib10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jsat.2010.01.008","article-title":"Symptom complaints of patients prescribed either oral methadone or injectable heroin","volume":"38","author":"Dursteler-MacFarland","year":"2010","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.biopsych.2020.02.014_bib11","first-page":"684","article-title":"Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment","volume":"5","author":"Hallinan","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.biopsych.2020.02.014_bib12","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/j.1360-0443.1997.tb02866.x","article-title":"Patterns of symptom complaints in methadone maintenance patients","volume":"92","author":"Dyer","year":"1997","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2020.02.014_bib13","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1080\/14656566.2016.1232391","article-title":"High prevalence of constipation and reduced quality of life in opioid-dependent patients treated with opioid substitution treatments","volume":"17","author":"Lugoboni","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.biopsych.2020.02.014_bib14","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1046\/j.1360-0443.1998.93913859.x","article-title":"Six deaths linked to concomitant use of buprenorphine and benzodiazepines","volume":"93","author":"Reynaud","year":"1998","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2020.02.014_bib15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00228-011-1122-4","article-title":"Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning","volume":"68","author":"Hakkinen","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.biopsych.2020.02.014_bib16","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000018953","article-title":"Outpatient opiate detoxification treatment with buprenorphine. Preliminary investigation","volume":"4","author":"Diamant","year":"1998","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.biopsych.2020.02.014_bib17","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/sj.npp.1300435","article-title":"Methadone maintenance reduces heroin- and cocaine-induced relapse without affecting stress-induced relapse in a rodent model of poly-drug use","volume":"29","author":"Leri","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2020.02.014_bib18","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1523\/JNEUROSCI.16-05-01957.1996","article-title":"Relapse to heroin-seeking in rats under opioid maintenance: The effects of stress, heroin priming, and withdrawal","volume":"16","author":"Shaham","year":"1996","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2020.02.014_bib19","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/sj.npp.1300712","article-title":"Rats maintained chronically on buprenorphine show reduced heroin and cocaine seeking in tests of extinction and drug-induced reinstatement","volume":"30","author":"Sorge","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2020.02.014_bib20","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/ejn.13955","article-title":"Role of mu, but not delta or kappa, opioid receptors in context-induced reinstatement of oxycodone seeking","volume":"50","author":"Bossert","year":"2019","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.biopsych.2020.02.014_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1037\/0735-7044.116.1.169","article-title":"Renewal of drug seeking by contextual cues after prolonged extinction in rats","volume":"116","author":"Crombag","year":"2002","journal-title":"Behav Neurosci"},{"key":"10.1016\/j.biopsych.2020.02.014_bib22","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1124\/jpet.112.201616","article-title":"A\u00a0G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine","volume":"344","author":"DeWire","year":"2013","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2020.02.014_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0272-7358(91)90091-8","article-title":"Sources of relapse after extinction in Pavlovian and instrumental learning","volume":"11","author":"Bouton","year":"1991","journal-title":"Clin Psychol Rev"},{"key":"10.1016\/j.biopsych.2020.02.014_bib24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.tips.2014.04.007","article-title":"Biased ligands at G-protein-coupled receptors: Promise and progress","volume":"35","author":"Violin","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.biopsych.2020.02.014_bib25","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cell.2017.10.035","article-title":"Bias factor and therapeutic window correlate to predict safer opioid analgesics","volume":"171","author":"Schmid","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.biopsych.2020.02.014_bib26","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1177\/0269881116689257","article-title":"Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents","volume":"31","author":"Altarifi","year":"2017","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.biopsych.2020.02.014_bib27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41467-018-08162-1","article-title":"Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects","volume":"10","author":"Kliewer","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.biopsych.2020.02.014_bib28","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1111\/bph.14224","article-title":"The novel mu-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception","volume":"175","author":"Hill","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2020.02.014_bib29","first-page":"2413","article-title":"A\u00a0randomized, Phase IIb study investigating oliceridine (TRV130), a novel micro-receptor G-protein pathway selective (mu-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty","volume":"10","author":"Singla","year":"2017","journal-title":"J\u00a0Pain Res"},{"key":"10.1016\/j.biopsych.2020.02.014_bib30","first-page":"927","article-title":"APOLLO-1: A randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the micro-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy","volume":"12","author":"Viscusi","year":"2019","journal-title":"J\u00a0Pain Res"},{"key":"10.1016\/j.biopsych.2020.02.014_bib31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/j.pain.0000000000000363","article-title":"A\u00a0randomized, phase 2 study investigating TRV130, a biased ligand of the mu-opioid receptor, for the intravenous treatment of acute pain","volume":"157","author":"Viscusi","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.biopsych.2020.02.014_bib32","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/papr.12801","article-title":"APOLLO-2: A randomized, placebo and active-controlled phase iii study investigating oliceridine (TRV130), a G protein-biased ligand at the mu-opioid receptor, for management of moderate to severe acute pain following abdominoplasty","volume":"19","author":"Singla","year":"2019","journal-title":"Pain Pract"},{"key":"10.1016\/j.biopsych.2020.02.014_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.pbr.2015.08.004","article-title":"Animal models of drug relapse and craving: From drug priming-induced reinstatement to incubation of craving after voluntary abstinence","volume":"224","author":"Venniro","year":"2016","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.biopsych.2020.02.014_bib34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41386-018-0234-2","article-title":"Relapse to opioid seeking in rat models: Behavior, pharmacology and circuits","volume":"44","author":"Reiner","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2020.02.014_bib35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s002130050496","article-title":"Predictive validity of the extinction\/reinstatement model of drug craving","volume":"135","author":"Fuchs","year":"1998","journal-title":"Psychopharamacology"},{"issue":"Pt B","key":"10.1016\/j.biopsych.2020.02.014_bib36","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.neuropharm.2013.06.007","article-title":"Extinction of drug seeking: Neural circuits and approaches to augmentation","volume":"76","author":"McNally","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2020.02.014_bib37","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1046\/j.1360-0443.2001.967104914.x","article-title":"Needle fixation, the drug user\u2019s perspective: A qualitative study","volume":"96","author":"McBride","year":"2001","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2020.02.014_bib38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.1360-0443.2002.00014.x","article-title":"Applying extinction research and theory to cue-exposure addiction treatments","volume":"97","author":"Conklin","year":"2002","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2020.02.014_bib39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1037\/1064-1297.4.1.5","article-title":"Priming effects with drugs and other reinforcers","volume":"4","author":"de Wit","year":"1996","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2020.02.014_bib40","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/0024-3205(87)90585-6","article-title":"Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists","volume":"40","author":"Portoghese","year":"1987","journal-title":"Life Sci"},{"key":"10.1016\/j.biopsych.2020.02.014_bib41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/1570159043359477","article-title":"Buprenorphine: A unique drug with complex pharmacology","volume":"2","author":"Lutfy","year":"2004","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.biopsych.2020.02.014_bib42","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.neuropharm.2018.02.017","article-title":"Changes in brain oxygen and glucose induced by oxycodone: Relationships with brain temperature and peripheral vascular tone","volume":"133","author":"Solis","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2020.02.014_bib43","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrn3104","article-title":"Opiate versus psychostimulant addiction: The differences do matter","volume":"12","author":"Badiani","year":"2011","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.biopsych.2020.02.014_bib44","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00213-013-3120-y","article-title":"The reinstatement model of drug relapse: Recent neurobiological findings, emerging research topics, and translational research","volume":"229","author":"Bossert","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2020.02.014_bib45","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1523\/JNEUROSCI.22-09-03321.2002","article-title":"Neural systems underlying opiate addiction","volume":"22","author":"De Vries","year":"2002","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.biopsych.2020.02.014_bib46","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0149-7634(89)80021-1","article-title":"Opiate reward: sites and substrates","volume":"13","author":"Wise","year":"1989","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.biopsych.2020.02.014_bib47","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0031-6997(24)01405-4","article-title":"Opioids, reward and addiction: An encounter of biology, psychology, and medicine","volume":"51","author":"Van Ree","year":"1999","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.biopsych.2020.02.014_bib48","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41583-018-0028-x","article-title":"Opioid receptors: Drivers to addiction?","volume":"19","author":"Darcq","year":"2018","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.biopsych.2020.02.014_bib49","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8369.1","article-title":"Neurobiology of opioid dependence in creating addiction vulnerability","volume":"5","author":"Evans","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.biopsych.2020.02.014_bib50","first-page":"27937","article-title":"Opioid drugs in maintenance and detoxification treatment of opiate addiction; addition of buprenorphine and buprenorphine combination to list of approved opioid treatment medications","volume":"68","year":"2003","journal-title":"Fed Regist"},{"key":"10.1016\/j.biopsych.2020.02.014_bib51","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00213-006-0485-1","article-title":"The effects of chronic buprenorphine on intake of heroin and cocaine in rats and its effects on nucleus accumbens dopamine levels during self-administration","volume":"188","author":"Sorge","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2020.02.014_bib52","series-title":"Goodman and Gilman\u2019s the Pharmacological Basis of Therapeutics","first-page":"522","article-title":"Drug addiction and drug abuse","author":"Jaffe","year":"1990"},{"key":"10.1016\/j.biopsych.2020.02.014_bib53","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF02243995","article-title":"Tolerance and dependence after continuous morphine infusion from osmotic pumps measured by operant responding in rats","volume":"100","author":"Adams","year":"1990","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2020.02.014_bib54","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF02244087","article-title":"Differential cross-tolerance to mu and kappa opioid agonists in morphine-tolerant rats responding under a schedule of food presentation","volume":"103","author":"Picker","year":"1991","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2020.02.014_bib55","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1476-5381.1977.tb07533.x","article-title":"The animal pharmacology of buprenorphine, an oripavine analgesic agent","volume":"60","author":"Cowan","year":"1977","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2020.02.014_bib56","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0022-3565(24)37431-2","article-title":"The effects of buprenorphine on self-administration of cocaine and heroin \u201cspeedball\u201d combinations and heroin alone by rhesus monkeys","volume":"285","author":"Mello","year":"1998","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2020.02.014_bib57","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1124\/jpet.105.095380","article-title":"Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: Effects of naloxone, buprenorphine, and methadone","volume":"317","author":"Negus","year":"2006","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2020.02.014_bib58","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/jcph.207","article-title":"First clinical experience with TRV130: Pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"54","author":"Soergel","year":"2014","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.biopsych.2020.02.014_bib59","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cpdd.721","article-title":"A\u00a0first-in-human clinical study with TRV734, an orally bioavailable G-protein-biased ligand at the \u03bc-opioid receptor","volume":"9","author":"James","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.biopsych.2020.02.014_bib60","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2020.02.014_bib61","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2019.01.020","article-title":"Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats","volume":"150","author":"Schwienteck","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2020.02.014_bib62","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.drugalcdep.2018.08.002","article-title":"The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats","volume":"192","author":"Zamarripa","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2020.02.014_bib63","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.tips.2018.08.007","article-title":"Abuse potential of biased mu opioid receptor agonists","volume":"39","author":"Negus","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.biopsych.2020.02.014_bib64","first-page":"485","article-title":"Combination of naloxone with buprenorphine in humans","volume":"95","author":"Weinhold","year":"1989","journal-title":"NIDA Res Monogr"},{"key":"10.1016\/j.biopsych.2020.02.014_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-006-0529-6","article-title":"Toward a model of drug relapse: An assessment of the validity of the reinstatement procedure","volume":"189","author":"Epstein","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2020.02.014_bib66","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1744-8069-9-45","article-title":"Sex differences in opioid analgesia and addiction: Interactions among opioid receptors and estrogen receptors","volume":"9","author":"Lee","year":"2013","journal-title":"Mol Pain"},{"key":"10.1016\/j.biopsych.2020.02.014_bib67","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41386-018-0125-6","article-title":"Sex differences in neural mechanisms mediating reward and addiction","volume":"44","author":"Becker","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2020.02.014_bib68","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.pbb.2006.11.022","article-title":"Sex differences in locomotor effects of morphine in the rat","volume":"85","author":"Craft","year":"2006","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2020.02.014_bib69","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.neuropharm.2019.02.008","article-title":"Respiratory depression and brain hypoxia induced by opioid drugs: Morphine, oxycodone, heroin, and fentanyl","volume":"151","author":"Kiyatkin","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2020.02.014_bib70","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fnint.2018.00044","article-title":"Central and peripheral mechanisms underlying physiological and drug-induced fluctuations in brain oxygen in freely-moving rats","volume":"12","author":"Kiyatkin","year":"2018","journal-title":"Front Integr Neurosci"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322320301037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322320301037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:12:17Z","timestamp":1777392737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322320301037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":70,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0006322320301037"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2020.02.014","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In a Rat Model of Opioid Maintenance, the G Protein\u2013Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain Hypoxia","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2020.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc on behalf of Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}